Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Jetstar to Charge for Overhead Cabin Bags From February 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
CANTON, Mass., March 19, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Shirley Kuhlmann to the newly created position of Executive Vice President and General Counsel and Secretary, effective March 16, 2018. Ms. Kuhlmann will oversee all legal and compliance matters for the company.
“We are pleased to have Shirley join our leadership team at this exciting time,” said Mike Heffernan, Collegium’s CEO. “Shirley’s previous role at Pepper Hamilton combined with her in-depth knowledge and understanding of Collegium, will bring immediate value as we execute our growth strategy.”
Prior to joining Collegium, Ms. Kuhlmann was a Partner in the Health Sciences Department of Pepper Hamilton LLP, where she served as Collegium’s outside counsel. Ms. Kuhlmann has over a decade of experience working with both private and public companies on a range of commercial and transactional matters, including financings, corporate governance and disclosure matters, and mergers and acquisitions and other business combination transactions. Ms. Kuhlmann holds a B.A. in Economics/Political Science from Columbia University and a J.D. from Emory University School of Law.
“I have been honored to represent Collegium as outside counsel, and I am very excited to be joining the team at this pivotal time in the Company’s development. I look forward to working with this proven management team and executing on Collegium’s mission to become the leader in responsible pain management,” commented Ms. Kuhlmann.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
